Takeda Pharmaceutical reported first-quarter fiscal 2026 results that were in line with its full-year outlook, as growth from core brands and newer products largely offset expected declines in its mature portfolio. Revenue totaled JPY 1.22 trillion, up 10.2% on an actual foreign-exchange basis but down 0.5% at constant exchange rates, while core operating profit was JPY 358.9 billion, rising 11.5% on an actual FX basis and declining 0.5% at constant exchange rates. Core inline brands, which represented 58% of total revenue, grew 2.3% at constant exchange rates, led by a 4% constant-currency increase for ENTYVIO, and new launches representing 4% of revenue grew 22.6% at constant exchange rates, supported by FRUZAQLA, LIVTENCITY, ADZYNMA and QDENGA. The company left its fiscal 2026 guidance unchanged and said it remains on track to generate JPY 650 billion to JPY 750 billion in free cash flow for the year. Takeda also highlighted preparations for three potential product launches: ORZEYFUL for narcolepsy type 1, rusfertide for polycythemia vera, and zasocitinib for psoriasis, with rusfertide receiving FDA priority review and an August PDUFA date.
Takeda Pharmaceutical Co. Ltd.Q1 results in line with full-year outlook, guidance unchanged, and free cash flow target reaffirmed.